Detail of "110267-81-7"

Reference

Comparison of chemosensitivity tests: clonogenic assay versus MTT assay

Comparison of chemosensitivity tests: clonogenic assay versus MTT assay. Kawada, Kazuhiko; Yonei, Toshiro; Ueoka, Hiroshi; Kiura, Katsuyuki; Tabata, Masahiro; Takigawa, Nagio; Harada, Mine; Tanimoto, Mitsune (Department of Internal Medicine II, Okayama University Medical School, Okayama 700-8558, Japan).In this study， 110267-81-7 and 97682-44-5 are also used. Acta Medica Okayama, 56(3), 129-134 (English) 2002 Okayama University Medical School. CODEN: AMOKAG. ISSN: 0386-300X. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) When the development of chemotherapeutic agents reaches the clin. trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coeff. between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogs (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was obsd. in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogs, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, esp. the platinum analogs and anthracyclines/anthracenedione. .

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: thoracic oncology research group study 0301

All Rights Reserved. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: thoracic oncology research group study 0301. Onoda, Sayaka; Masuda, Noriyuki; Seto, Takashi; Eguchi, Kenji; Takiguchi, Yuichi; Isobe, Hiroshi; Okamoto, Hiroaki; Ogura, Takashi; Yokoyama, Akira; Seki, Nobuhiko; Asaka-Amano, Yoshiko; Harada, Masao; Tagawa, Akihiro; Kunikane, Hiroshi; Yokoba, Masanori; Uematsu, Kazutsugu; Kuriyama, Takayuki; Kuroiwa, Yumi; Watanabe, Koshiro (Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan). Journal of Clinical Oncology, 24(34), 5448-5453 (English) 2006 American Society of Clinical Oncology. CODEN: JCONDN. ISSN: 0732-183X. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Purpose: This multicenter, phase II study was conducted to evaluate the activity of amrubicin, a topoisomerase II inhibitor, against refractory or relapsed small-cell lung cancer (SCLC). Patients and Methods: SCLC patients with measurable disease who had been treated previously with at least one platinum-based chemotherapy regimen and had an Eastern Cooperative Oncol. Group performance status of 0 to 2 were eligible. Two groups of patients were selected: patients who experienced first-line treatment failure less than 60 days from treatment discontinuation (refractory group), and patients who responded to first-line treatment and experienced disease progression 3 60 days after treatment discontinuation (sensitive group). Amrubicin was administered as a 5-min daily i.v. injection at a dose of 40 mg/m2 for 3 consecutive days, every 3 wk. Results: Between June 2003 and Dec.Several reagents with their cas registry numbers 142805-56-9 and 110267-81-7 are used here. 2004, 60 patients (16 refractory and 44 sensitive) were enrolled. The median no. of treatment cycles was four (range, one to eight). Grade 3 or 4 hematol. toxicities comprised neutropenia (83%), thrombocytopenia (20%), and anemia (33%). Febrile neutropenia was obsd. in three patients (5%). Nonhematol. toxicities were mild. No treatment-related death was obsd. The overall response rates were 50% (95% CI, 25% to 75%) in the refractory group, and 52% (95% CI, 37% to 68%) in the sensitive group. The progression-free survival, overall survival, and 1-yr survival in the refractory group and the sensitive group were 2.6 and 4.2 mo, 10.3 and 11.6 mo, and 40% and 46%, resp. Conclusion: Amrubicin exhibits significant activity against SCLC, with predictable and manageable toxicities; this agent deserves to be studied more extensively in addnl. trials. .